Form DEFA14A MAIA Biotechnology, Inc.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☒
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material Pursuant to Rule 14a-ll (c) or Rule 14a-12
|
|
MAIA Biotechnology, Inc.
|
|
(Name of Registrant as Specified In Its Charter)
|
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
No fee required.
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
- Hyperscale Data Has Sold Approximately 685 Bitcoin for Approximately $43 Million, Reduces Debt by Approximately $30 Million and Strengthens Liquidity to Support Michigan Data Center Buildout
- TerraPower Accelerates Natrium® Reactor Deployment Following Landmark Meetings with Korean Leaders
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
